公开(公告)号：US20130337041A1

公开(公告)日：2013-12-19

申请号：US13776515

申请日：2013-02-25

申请人： Cerenis Therapeutics, S.A. ,  Ottawa Heart Institute Research Corporation

发明人： Daniel L. SPARKS

IPC分类号： A61K31/685 ,  A61K31/683

CPC分类号： A61K31/685 ,  A61K31/66 ,  A61K31/663 ,  A61K31/683 ,  A61K2300/00

摘要： The invention provides a pharmaceutical composition comprising a synthetic or naturally occurring charged phospholipid, which is formulated into a dosage form for administration to a subject or which is administered as a food additive. Negatively charged phospholipid composition increase the net negative charge on intravascular lipoproteins, enhance the clearance of cholesterol and regulate the function of lipolytic enzymes, retard prothrombin formation and aid in the clearance of virus and bacterial particles. Negatively charged lipid compositions can therefore be administered to humans and animals for the treatment of hyperlipidemia and blood coagulation disorders and to reduce the levels of virus, bacteria, and endotoxins in the blood stream. Positively charged lipid compositions can be administered to delay lipoprotein clearance from the plasma compartment and give longer duration of activity for drugs which are associated with lipoproteins.

摘要翻译： 本发明提供包含合成或天然存在的带电磷脂的药物组合物，其被配制成用于给予受试者或作为食物添加剂施用的剂型。 负电荷的磷脂组合物增加血管内脂蛋白的净负电荷，增强胆固醇的清除率并调节脂肪分解酶的功能，阻止凝血酶原的形成，并帮助清除病毒和细菌颗粒。 因此，负电荷的脂质组合物可以施用于人和动物用于治疗高脂血症和凝血障碍并降低血流中的病毒，细菌和内毒素的水平。 可以施用带正电的脂质组合物以延迟来自血浆隔室的脂蛋白清除，并为与脂蛋白相关的药物提供更长的活性持续时间。